These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 9467924)

  • 1. Susceptibilities of 97 strains of Xanthomonas maltophilia to antibiotics and the effect of beta-lactamase inhibitors.
    Ismaeel NA
    Microbios; 1997; 91(367):97-103. PubMed ID: 9467924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
    Sader HS; Tosin I; Sejas L; Miranda E
    Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of antimicrobial resistance of Acinetobacter baumannii clinical isolates from Shanghai and Hong Kong.
    Ling TK; Ying CM; Lee CC; Liu ZK
    Med Princ Pract; 2005; 14(5):338-41. PubMed ID: 16103700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro susceptibility of 124 Xanthomonas maltophilia (Stenotrophomonas maltophilia) isolates: comparison of the agar dilution method with the E-test and two agar diffusion methods.
    Arpi M; Victor MA; Mortensen I; Gottschau A; Bruun B
    APMIS; 1996 Feb; 104(2):108-14. PubMed ID: 8619912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Susceptibilities of 123 strains of Xanthomonas maltophilia to eight beta-lactams (including beta-lactam-beta-lactamase inhibitor combinations) and ciprofloxacin tested by five methods.
    Pankuch GA; Jacobs MR; Rittenhouse SF; Appelbaum PC
    Antimicrob Agents Chemother; 1994 Oct; 38(10):2317-22. PubMed ID: 7840563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [In vitro activity of 9 antibiotics and 3 beta-lactamase inhibitors against 107 clinical isolates of Acinetobacter baumanii].
    Echeverría MJ; López de Goicoechea MJ; Ayarza R; Vecino Y; Lazpita MA; Ibarretxebea AB; Barbier A; Cruz González M; Martínez de la Fuente P
    Enferm Infecc Microbiol Clin; 1997; 15(6):319-22. PubMed ID: 9376404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [In vitro activity of beta-lactam agents and beta-lactamase inhibitors in clinical isolates of Acinetobacter baumannii].
    López-Hernández S; Alarcón T; Delgado T; de Las Cuevas MC; López-Brea M
    Rev Esp Quimioter; 1999 Jun; 12(2):140-3. PubMed ID: 10562675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Surveillance of antimicrobial resistance among nosocomial gram-negative pathogens from 15 teaching hospitals in China in 2005].
    Yang QW; Xu YC; Chen MJ; Hu YJ; Ni YX; Sun JY; Yu YS; Kong HS; He L; Wu WY; Ye HF; Yang YM; Zhu LN; Guo SH; Ji P; Zhu ZH; Ren JK; Zhang LX; Sun ZY; Zhu XH; Tong MQ; Zhao WS; Mei YN; Liu Y; Zhang ZJ; Duan Q; Li D; Liu PP; Wang J; Han LX; Wang H; Xie XL
    Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(39):2753-8. PubMed ID: 18167265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamic study of beta-lactams alone and in combination with beta-lactamase inhibitors against Pseudomonas aeruginosa possessing an inducible beta-lactamase.
    Li C; Nicolau DP; Lister PD; Quintiliani R; Nightingale CH
    J Antimicrob Chemother; 2004 Feb; 53(2):297-304. PubMed ID: 14729755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of in vitro activities of levofloxacin, ciprofloxacin, ceftazidime, cefepime, imipenem, and piperacillin-tazobactam against aerobic bacterial pathogens from patients with nosocomial infections.
    Huang SS; Lee SC; Lee N; See LC; Tsai MH; Shieh WB
    J Microbiol Immunol Infect; 2007 Apr; 40(2):134-40. PubMed ID: 17446961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance of Xanthomonas maltophilia to antibiotics and the effect of beta-lactamase inhibitors.
    Neu HC; Saha G; Chin NX
    Diagn Microbiol Infect Dis; 1989; 12(3):283-5. PubMed ID: 2791491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Susceptibility of 100 strains of Stenotrophomonas maltophilia to three beta-lactams and five beta-lactam-beta-lactamase inhibitor combinations.
    Lecso-Bornet M; Bergogne-Bérézin E
    J Antimicrob Chemother; 1997 Nov; 40(5):717-20. PubMed ID: 9421322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of newer broad spectrum beta-lactam antibiotics against enterobacteriaceae and non-fermenters: a report from Austrian intensive care units. Austrian Carbapenem Susceptibility Surveillance Group.
    Krause R; Mittermayer H; Feierl G; Allerberger F; Wendelin I; Hirschl A; Reisinger EC
    Wien Klin Wochenschr; 1999 Jul; 111(14):549-54. PubMed ID: 10467641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Beta-lactam resistance in aquatic Enterobacter cloacae strains using phenotypic and genotypic criteria].
    Lazăr V; Cernat R; Balotescu C; Cotar A; Coipan E; Cojocaru C
    Bacteriol Virusol Parazitol Epidemiol; 2002; 47(3-4):185-91. PubMed ID: 15085610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative antianaerobic activity of BMS 284756.
    Hoellman DB; Kelly LM; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 2001 Feb; 45(2):589-92. PubMed ID: 11158759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of beta-lactamase inhibitors on minimum inhibitory concentration of ampicillin and amoxicillin for Staphylococcus aureus strains.
    Paniagua GL; Monroy E; García O; Vaca S
    Rev Latinoam Microbiol; 1998; 40(3-4):128-34. PubMed ID: 10932741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Susceptibility of Xanthomonas maltophilia and amikacin-resistant gram-negative bacteria to newer antimicrobials.
    Matsuyama JR; Beail B; Wallis C; Zeleznik D; Tartaglione T
    Clin Pharm; 1991 Jul; 10(7):544-8. PubMed ID: 1860303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antimicrobial susceptibility pattern of nosocomial gram negative pathogens: results from MYSTIC study in Hacettepe University Adult Hospital (2000-2004)].
    Zarakolu P; Hasçelik G; Unal S
    Mikrobiyol Bul; 2006 Jul; 40(3):147-54. PubMed ID: 17001842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Characterization of the resistance to combinations of beta lactams and inhibitors of beta-lactamases in Escherichia coli. Effect of the type and amount of beta-lactamase production].
    del Mar Pérez-Moreno M; Pous-Miralles G; Romera-Sastre G; Panisello-Bertomeu JM; Jardí-Baiges AM; Zarazoga-López J
    Enferm Infecc Microbiol Clin; 1997 Nov; 15(9):477-81. PubMed ID: 9527373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring the effectiveness of tazobactam against ceftazidime resistant Escherichia coli: insights from the comparison between susceptibility testing and beta-lactamase inhibition.
    Bethel CR; Hujer AM; Helfand MS; Bonomo RA
    FEMS Microbiol Lett; 2004 May; 234(1):99-103. PubMed ID: 15109726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.